Sign In
Buy BDTX
$1.61
-0.0500 (-3.01%)
At Close: Jun 22, 2026
CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic
Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?
12:30pm, Wednesday, 15'th Apr 2026
Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock?
BDTX and Brain Metastases: Why CNS Activity Could Matter in 2026
01:26pm, Thursday, 09'th Apr 2026
BDTX spotlights silevertinib's 86% CNS response in NSCLC, with 2026 durability data and a glioblastoma push shaping its brain-metastasis strategy.
Black Diamond Stock: Weighing Catalysts vs. Concentration
01:21pm, Thursday, 09'th Apr 2026
BDTX hinges on silevertinib's mutation breadth and CNS activity, with 2026 data, cash runway, and partnership moves set to shape its high-risk, high-reward path.
BDTX: What Silevertinib Data Say About EGFR NSCLC Upside
01:16pm, Thursday, 09'th Apr 2026
BDTX bets on silevertinib's broad EGFR mutation reach and CNS activity, but with no approved products, upcoming 2026 data and partnerships are pivotal.
Black Diamond Therapeutics: Market Is Yawning About These Data, But I See Opportunity
08:53am, Wednesday, 25'th Mar 2026
Black Diamond Therapeutics (BDTX) remains a 'Buy', as silevertinib shows promising efficacy in EGFR-mutant NSCLC with notable CNS activity. BDTX reported a 60% objective response rate and 86% CNS resp
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
04:01pm, Monday, 16'th Mar 2026
CAMBRIDGE, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
04:01pm, Monday, 02'nd Mar 2026
CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic
Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year?
10:41am, Friday, 23'rd Jan 2026
Here is how Black Diamond (BDTX) and Bionano Genomics, Inc. (BNGO) have performed compared to their sector so far this year.
What Makes Black Diamond (BDTX) a New Strong Buy Stock
01:00pm, Friday, 09'th Jan 2026
Black Diamond (BDTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for January 9th
07:26am, Friday, 09'th Jan 2026
BDTX, LUMN, ADEA, ACRE and TACT have been added to the Zacks Rank #1 (Strong Buy) List on January 9th, 2026.
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Recommendation of “Moderate Buy” from Brokerages
01:23am, Friday, 02'nd Jan 2026
Shares of Black Diamond Therapeutics, Inc. (NASDAQ: BDTX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight brokerages that are currently covering the stock,
Comparing Iovance Biotherapeutics (NASDAQ:IOVA) & Black Diamond Therapeutics (NASDAQ:BDTX)
03:17am, Thursday, 25'th Dec 2025
Black Diamond Therapeutics (NASDAQ: BDTX - Get Free Report) and Iovance Biotherapeutics (NASDAQ: IOVA - Get Free Report) are both small-cap medical companies, but which is the better business? We will
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Recommendation of “Moderate Buy” from Brokerages
01:10am, Monday, 08'th Dec 2025
Shares of Black Diamond Therapeutics, Inc. (NASDAQ: BDTX - Get Free Report) have been given an average rating of "Moderate Buy" by the eight ratings firms that are presently covering the firm, MarketB
Down 30.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)
10:35am, Thursday, 04'th Dec 2025
Black Diamond (BDTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revi
